MRNA - Latest News

Moderna, Inc. (MRNA), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $90.38B. Beta to the broader market is 0.90.

The article list below shows the most recent MRNA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent MRNA Headlines

He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment

247wallst.com - Nov 14, 2026

A retiree on Original Medicare finishes melanoma surgery and hears about a personalized vaccine that could cut his odds of relapse. Whether he can ge

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

fool.com - Nov 14, 2026

Axsome Therapeutics is experiencing rapid revenue growth driven by its portfolio of central nervous system treatments. Moderna is diversifying its me

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

zacks.com - Nov 13, 2026

MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.

Moderna, Inc. $MRNA Stock Sold by Commonwealth Equity Services LLC

defenseworld.net - Nov 13, 2026

Commonwealth Equity Services LLC lowered its stake in Moderna, Inc. (NASDAQ: MRNA) by 17.

BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.

barrons.com - Nov 13, 2026

BioNTech has multiple catalysts that could generate a rally of 35% for the stock.

How News Affects MRNA Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track MRNA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked MRNA news questions

What is the latest MRNA news headline?
The most recent MRNA headline (Nov 14, 2026) is "He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
How fresh is the MRNA news on this page?
News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
What MRNA news moves options pricing?
Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
How can I track unusual MRNA options activity related to news?
Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.